Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
← catalyst calendarNCT07228832 · readout in 650 d
Sponsored by Summit Therapeutics (industry) · SMMT — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
600estimated
Sites
166
Countries
Belgium, Canada, Czechia +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-18 | actual | When the study began enrolling |
| Primary completion | 2028-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Colorectal Cancer (CRC)
Interventions
- Drug: Drug: Ivonescimab Injection — also filed as Oxaliplatin, Leucovorin, 5-Fluorouracil
- Drug: Drug: Bevacizumab Injection — also filed as Oxaliplatin, Leucovorin, 5-Fluorouracil
Primary outcome
what the primary-completion date above is the date OFPFS by IRRC based on RECIST v1.1
measured Up to approximately 2.5 years
Permalink · SMMT's whole pipeline · Catalyst calendar · Every registered study · What changed